ClinicalTrials.gg
Not yet recruitingNCT07729475Updated Jul 27, 2026

A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Oral SAL0137 in Adults With Elevated Lp(a) and Increased Risk of Cardiovascular Events

A Phase 2 interventional study of SAL0137 Dose 1 and SAL0137 Dose 2 in Elevated Lipoprotein(a), sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-27.

Sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 113 studies in Atherosclerosis with a site in China — 36 open to participants now, 48 under way, 11 of them phase 3. Atherosclerosis · China.

Planned enrollment
52nd of 79
120 · median 200
Started
2026
with 14 others
Phase 2
6 of 113
4 open now
Primary completion
2026-12
later than 20 of 47 live
Registered
108th of 113
by date

Among the 113 studies in Atherosclerosis with a site in China, this one is the 52nd largest by planned enrollment of the 79 interventional ones that give a count, is one of 15 that started in 2026, is one of 6 in phase 2, reaches primary completion later than 20 of the 47 other live ones, and was the 108th registered.

Atherosclerosis

1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.

Browse Atherosclerosis studies →

Open to participants now

36 of the 113 studies in Atherosclerosis with a site in China are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 164 Atherosclerosis studies recruiting now, 86 (52%) set no upper age limit and 34 (21%) stop at 75 or younger; 16 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies in Atherosclerosis with a site in China, or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled Phase II trial evaluating the efficacy and safety of oral SAL0137 in adults with elevated Lp(a) and high cardiovascular risk. Participants will be randomized 1:1:1:1 to receive low-dose SAL0137, medium-dose SAL0137, high-dose SAL0137, or placebo for a treatment period of 12 weeks. The study assesses changes in Lp(a) levels and safety parameters.

03

Conditions studied

  • Elevated Lipoprotein(a)

Browse trials for

Keywords

  • SAL0137
  • Elevated Lipoprotein(a)
  • Phase II
  • Atherosclerotic Cardiovascular Disease (ASCVD)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged ≥ 18 years on the date of signing the form, male or female;
  2. (BMI) within the range of 18.5 to 40.0 kg/m² (inclusive);
  3. Participants must be at elevated risk for cardiovascular events;
  4. Lp(a) ≥ 150 nmol/L (or ≥ 60 mg/dL) at screening or prior to randomization;
  5. Participants receiving the following medications at screening must have been on a stable regimen for the specified duration prior to screening and prior to randomization, and are expected to remain on a stable regimen throughout the study
  6. Compliance with study drug administration during the run-in period prior to randomization must be between 80% and 120%;
  7. Participants (including their partners) must be willing to voluntarily adopt highly effective measures from the time of signing the informed consent form until 3 months after the last dose of study drug (see Appendix 2); female participants of must have a negative pregnancy test (serum) and must not be breastfeeding;
  8. Fully understand the objectives and requirements of this study, voluntarily participate in the clinical trial and sign the written informed consent form, and be willing and able to comply with the visit, treatment, and examination procedures specified in the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Experienced any of the following within 3 months prior to screening or prior to randomization: myocardial infarction or unstable angina, stroke or , acute limb ischemia, hemorrhagic stroke or other major bleeding history, major cardiac or non-cardiac surgery, coronary, carotid, or peripheral artery revascularization; or other events that, in the investigator's opinion, indicate clinical instability;
  2. Planned cardiac, cerebrovascular, or peripheral artery surgery, or coronary revascularization, or other major surgery after randomization;
  3. Active , or history of malignancy within 5 years prior to screening (except for basal cell carcinoma of the skin or carcinoma in situ of the cervix that have been radically resected);
  4. Previous history of diseases that significantly affect lipid levels, such as nephrotic syndrome, severe liver disease, Cushing's syndrome, etc.;
  5. History of acute kidney injury within 12 months prior to screening;
  6. Uncontrolled hyperthyroidism or hypothyroidism;
  7. Uncontrolled type 1 or type 2 diabetes mellitus within 6 months prior to screening (including diabetic ketoacidosis or hyperglycemic hyperosmolar state, or > 8.5% at screening);
  8. Active infection requiring systemic anti-infective therapy (oral or intravenous) prior to randomization, and the infection has not clinically resolved or still requires continued anti-infective treatment prior to randomization;
  9. (NYHA) Class III or IV cardiac function prior to screening;
  10. Lipoprotein apheresis within 3 months prior to screening, or planned during the study period;
  11. Use of weight-loss medications (see Appendix 3) or undergone surgery causing weight instability within 2 months prior to screening;
  12. Long-term continuous or repeated use of systemic within 3 months prior to screening;
  13. Known allergy to the active ingredient or any of SAL0137;
  14. Uncontrolled hypertension at screening or prior to randomization (office sitting systolic blood pressure ≥ 160 mmHg and/or office sitting diastolic blood pressure ≥ 100 mmHg);
  15. Estimated (eGFR) \< 30 mL/min/1.73 m² at screening or prior to randomization (calculated using the CKD-EPI 2021 formula, see Appendix 4), or undergoing dialysis;
  16. (ALT), aspartate aminotransferase (AST), or gamma-glutamyl transferase (GGT) > 3 × (ULN), or total > 2 × ULN at screening or prior to randomization;
  17. Fasting triglycerides ≥ 5.6 mmol/L at screening or prior to randomization;
  18. Creatine kinase (CK) > 3 × ULN at screening or prior to randomization;
  19. Thyroid-stimulating hormone (TSH) \< lower limit of normal (LLN) or > 1.5 × ULN at screening or prior to randomization;
  20. History of drug or alcohol abuse or dependence within 6 months prior to screening (average weekly alcohol intake > 14 standard units; 1 unit = 285 mL beer, or 25 mL spirits, or 100 mL wine);
  21. Positive virology test results at screening, including surface antigen (if positive, the investigator may decide whether to perform HBV-DNA quantification), antibody, antibody, and Treponema pallidum-specific antibody;
  22. Participation in any drug clinical trial and use of drug within 3 months prior to screening (or within 5 half-lives of the investigational drug, whichever is longer), or participation in any medical device clinical trial and use of a medical device;
  23. Any other reasons that, in the investigator's opinion, may affect the evaluation of efficacy and/or safety of this study, or make the participant unsuitable for participation in this clinical trial (including but not limited to poor compliance as judged by the investigator, or remote residence precluding scheduled follow-up visits).
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Test Group 1

    Drug: SAL0137 Dose 1

  • Experimental
    Test Group 2

    Drug: SAL0137 Dose 2

  • Experimental
    Test Group 3

    Drug: SAL0137 Dose 3

  • Placebo comparator
    Reference Group

    Drug: Placebo

Interventions

  • DrugSAL0137 Dose 1

    SAL0137 Tablets

  • DrugSAL0137 Dose 2

    SAL0137 Tablets

  • DrugSAL0137 Dose 3

    SAL0137 Tablets

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Percent Change from Baseline in Lipoprotein (a) Lp(a)

    Time frame: Baseline to Week 12

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Dec 2026, 4 months later.

Of 46 phase 2 interventional studies under Atherosclerosis, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 59. This study's planned 4 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2026
First posted
Jul 27, 2026
StartEst.
Jul 27, 2026
Primary completionEst.
Dec 12, 2026
CompletionEst.
Apr 30, 2027
Last update
Jul 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07729475
Responsible party
Sponsor
First posted
Jul 27, 2026
Start date
Jul 27, 2026 (estimated)
Primary completion
Dec 12, 2026 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Jul 27, 2026

Study contacts

Li
Contact
13521531013@163.com
13521531013

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion